MedTrace Logo

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

NCT07272057 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-12-09

No results posted yet for this study

Summary

The goal of this clinical trial

The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:

* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.

Participants will:

* Be adults diagnosed with advanced lung cancer and type 2 diabetes.
* Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
* Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Conditions

Interventions

DRUG

SGLT-2 inhibitor

SGLT2 inhibitors used for patients with lung cancer and diabetes

OTHER

Sham (No Treatment)

SGLT2 inhibitors are not used for patients with lung cancer and diabetes

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-07
Primary Completion
2026-10-07
Completion
2026-11-07

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272057 on ClinicalTrials.gov